ISRCTN75147488 https://doi.org/10.1186/ISRCTN75147488

A randomised trial of epirubicin and cyclophosphamide versus epirubicin and paclitaxel in the treatment of women with metastatic breast cancer

Submission date 28/02/2001	**Recruitment status** No longer recruiting	[_] Prospectively registered [_] Protocol [_] Statistical analysis plan [X] Results [_] Individual participant data
Registration date 28/02/2001	**Overall study status** Completed	
Last Edited 07/10/2009	**Condition category** Cancer	

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Dr Barbara Uscinska

Contact details
MRC Clinical Trials Unit
222 Euston Road
London
United Kingdom
NW1 2DA

Additional identifiers

ClinicalTrials.gov (NCT)
NCT00002953

Protocol serial number
AB01

Study information

Scientific Title

Study objectives
To compare epirubicin and paclitaxel versus epirubicin and cyclophosphamide in metastatic breast cancer

Ethics approval required
Old ethics approval format

Ethics approval(s)
Not provided at time of registration

Study design
Randomised controlled trial

Primary study design
Interventional

Study type(s)
Not Specified

Health condition(s) or problem(s) studied
Cancer

Interventions
Epirubicin and paclitaxel/epirubicin and cyclophosphamide

Intervention Type
Drug

Phase
Not Specified

Drug/device/biological/vaccine name(s)
epirubicin and cyclophosphamide versus epirubicin and paclitaxel

Primary outcome(s)
Progression free survival.

Key secondary outcome(s))
Overall survival, response, toxicity, quality of life (Fact-B Quality of Life, Questionnaire); and health economics (Cost and Resource Use Questionnaire).

Completion date
05/11/1999

Eligibility

Key inclusion criteria

1. Metastatic breast cancer previously untreated except in adjuvant setting
2. Exposure to anthracyclines limited
3. Treatment free interval more than 6 months
4. Normal ejection fraction

Participant type(s)
Patient

Healthy volunteers allowed
No

Age group
Not Specified

Sex
Female

Key exclusion criteria
History of cardiac disease

Date of first enrolment
01/12/1996

Date of final enrolment
05/11/1999

Locations

Countries of recruitment
United Kingdom

England

South Africa

Study participating centre
MRC Clinical Trials Unit
London
United Kingdom
NW1 2DA

Sponsor information

Organisation
Medical Research Council (MRC) (UK)

Funder(s)

Funder type
Research council

Funder Name
Medical Research Council (UK)

Alternative Name(s)
Medical Research Council (United Kingdom), UK Medical Research Council, MRC

Funding Body Type
Government organisation

Funding Body Subtype
National government

Location
United Kingdom

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary
Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	20/11/2005		Yes	No